CLAIMS

What is claimed is:

1. A method of treating a viral infection, the method comprising administering to an individual an effective amount of IFN-α and an effective amount of IFN-γ, and co-administering an amount of a non-pirfenidone/pirfenidone analog agent effective to reduce or eliminate the occurrence or severity of side effects that would normally be associated with the administration of IFN-α and IFN-γ.

2. The method of claim 1, wherein the individual has been exposed to a virus, and the IFN-γ and the IFN-α are administered within 24 hours of exposure to the virus.

3. The method of claim 1, wherein the individual has been exposed to a virus, and the IFN-γ and the IFN-α are administered within 48 hours of exposure to the virus.

4. The method of claim 1, wherein the individual has been exposed to a virus, and the IFN-γ and the IFN-α are administered 72 hours to 35 days after exposure to the virus.

5. The method of claim 1, wherein the IFN-γ and the IFN-α are administered subcutaneously.

6. The method of any one of claims 1-5, further comprising administering an effective amount of a nucleotide analog or a nucleoside analog.

7. The method of any one of claims 1-5, wherein the IFN-α is a consensus interferon.

8. A method of treating a viral infection, the method comprising administering to an individual an effective amount of IFN-α and an effective amount of IFN-γ, and co-administering an amount of a non-pirfenidone/pirfenidone analog agent effective to reduce or eliminate the occurrence or severity of pain that would normally be associated with the viral infection and/or the administration of IFN-α and IFN-γ.

9. The method of claim 8, wherein the IFN-γ and the IFN-α are administered subcutaneously.

10. The method of any one of claims 8, further comprising administering an effective amount of a nucleotide analog or a nucleoside analog.

11. The method of any one of claims 8-10, wherein the IFN-α is a consensus interferon.

12. The method of claim 8, wherein the non-pirfenidone/pirfenidone analog agent is a non-narcotic analgesic.

13. The method of claim 1, wherein the non-pirfenidone/pirfenidone analog agent is a non-narcotic analgesic.